MARKET

CURX

CURX

CURANEX PHARMACEUTICALS INC
NASDAQ
0.2549
-0.0193
-7.04%
After Hours: 0.2551 +0.0002 +0.08% 19:46 07/02 EDT
OPEN
0.2897
PREV CLOSE
0.2742
HIGH
0.2897
LOW
0.2549
VOLUME
76.07K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
0.2549
MARKET CAP
7.23M
P/E (TTM)
-0.9846
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 5d ago
Curanex shareholders back 1-for-10 to 1-for-50 reverse stock split to meet Nasdaq $1 bid rule
PUBT · 5d ago
Weekly Report: what happened at CURX last week (0622-0626)?
Weekly Report · 5d ago
Weekly Report: what happened at CURX last week (0615-0619)?
Weekly Report · 06/22 10:14
Curanex Pharmaceuticals files draft information statement (Form PRE 14C)
PUBT · 06/18 21:12
Wisdom Wealth Resources names Hao Xiaohui executive director, co-chairman
PUBT · 06/17 10:47
Weekly Report: what happened at CURX last week (0608-0612)?
Weekly Report · 06/15 10:15
More
About CURX
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

Webull offers Curanex Pharmaceuticals Inc stock information, including NASDAQ: CURX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CURX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CURX stock methods without spending real money on the virtual paper trading platform.